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ABSTRACT
In this paper we propose a new way of conceptualizing animals in 
experimentation: the animal-as-patient. Construing and treating ani-
mals as patients offers a way of successfully addressing some of the 
entrenched epistemological and ethical problems within a practice of 
animal experimentation directed to human clinical benefit. This ap-
proach is grounded in an epistemological insight and builds on work 
with so-called “pet models”. It relies upon the occurrence and charac-
terization of analogous human and nonhuman animal diseases, where, 
if certain criteria of homology and mechanism are met, the animal 
simultaneously becomes a patient and a spontaneous model of the 
human disease.
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1. Introduction
Experimentation on nonhuman animals for human clinical 
benefit is a highly contentious practice. In this paper we out-
line a new way of approaching animal experimentation through 
construing animals as patients. We argue that this approach can 
address some otherwise seemingly intractable epistemological 
and ethical concerns raised by research with animals. The paper 
will begin by setting out what the animal-as-patient involves, 
before showing how this new model can meet some of the epis-
temological and ethical challenges arising from animal experi-
mentation practices. Finally, we will turn to consider some of 
the limitations of re-conceptualizing animals in experimenta-
tion on the patient model. 
2. Who are animal patients?
As the name suggests, treating animals-as-patients involves 
regarding nonhuman animals in experimentation as akin to in-
dividual patients rather than mass-produced and expendable in-
struments or tools. Practically, it means enrolling animals into a 
clinical trial in a way analogous to that in which human patients 
are enrolled into multi-centre clinical trials (i.e., trials run si-
multaneously at a number of locations). When animal patients 
present to a veterinarian and are diagnosed with a condition or 
disease of interest for which experimental subjects are being 
sought, the owner of the animal is offered to allow or disallow 
the animal participation in the research. If an owner consents 
to their animal becoming a research participant, then they can 
remain in the owner’s care, and, depending on the nature of 
the experiment, they may continue to reside in their own home 
environment while participating in the research.
On our definition, animal patients share a number of key fea-
tures. Such patients should be what scientists call “natural” or 
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“spontaneous” models i.e., animals which, without deliberate 
human intervention, develop a condition or disease analogous 
to that found in humans. This distinguishes natural models from 
induced or transgenic ones where the disease or condition to be 
studied is brought about artificially in the experimental animal. 
In the case of induced models, otherwise healthy animals are 
subjected to an intervention that produces a specific disease or 
physiological condition, while transgenic disease models are 
genetically modified to create a disease or condition of inter-
est. For the purposes of this paper we are not concerned with 
defining what constitutes an analogous condition or disease 
and instead accept that researchers deploy this model category 
and have well-formulated criteria on which they do so. Finally, 
rather than being bred solely for the purpose of experimenta-
tion and housed in laboratory conditions, animal patients have 
some other form of value or use for their owners, e.g., they are 
assistance or companion animals, creatures used in agriculture, 
zoo animals etc.
Animal patients therefore lie between two existing model 
types used by scientists: natural models and pet models. As 
explained above, patient models are effectively a subset of 
natural models. While so-called “pet models” (companion ani-
mals recruited into research with pre-existing diseases or con-
ditions) are a subset of the larger cohort of potential animal 
patients, since pets only represent one source for animal pa-
tients. Clinical trials that employ the pet model are typically run 
from veterinary specialist centers and teaching hospitals. These 
otherwise owned and cared for experimental “patients” can be 
found in many domains of therapeutic research. For example 
veterinarians and biomedical researchers are currently working 
in partnership to develop techniques that use autologous adult 
stem cells to treat osteoarthritis in dogs (Black et al. 2008). 
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Therefore, although the animal-as-patient represents an in-
novative conceptual framework, it is worth noting that its rela-
tionship to existing scientific models demonstrates that it is not 
a fanciful or implausible category.
Before moving on to consider the advantages of construing 
animals as patients, we want to acknowledge an intellectual 
debt. The term “animal-as-patient” is our own, but has its gen-
esis in the work of both Stephen Pemberton (Pemberton 2004) 
and Donna Haraway (Haraway 2008). Pemberton (a medical 
historian) has outlined what might be regarded as the paradig-
matic case of a natural or spontaneous model—the develop-
ment of the canine model of hemophilia A. He describes how 
a particular litter of Irish Setters with a blood clotting disorder 
came to the attention of medical researchers in the 1940s. Key 
to this discovery were veterinarians at Cornell University who 
identified the resemblance between this canine pathology and a 
kind of hemophilia found in humans. Once alerted to the unique 
characteristics of these animals, medical researchers acquired 
the remainder of the litter and began a program of experimenta-
tion to further examine these similarities.
At first glance it might seem that these hemophilic dogs be-
came little more than a fruitful heuristic for investigations into 
human disease. However it is possible to argue that there is 
more going on here. In her 2008 book When Species Meet, Ha-
raway suggests that the manner in which experimentation was 
undertaken on these creatures and the intensive efforts required 
to simply keep them alive illustrates how the diseased animals 
became in some sense patients, rather than merely experimen-
tal tools. “The puppies had to become patients if they were to 
become technologies and models... Lab staff could not function 
as researchers if they did not function as caregivers. Dogs could 
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not work as models if they did not work as patients” (Haraway 
2008, 59). 
3. Meeting the epistemological and ethical chal-
lenges of animal experimentation  
The epistemological problem
The central epistemological problem for animal experimen-
tation directed to human clinical benefit revolves around as-
sessing the validity of extrapolation. This is the crucial step in 
translation when knowledge of the response of the animal mod-
el to an intervention is employed in an attempt to predict the 
likely effect of the intervention upon the human target. What 
has become increasingly apparent is that there is frequently a 
poor translation; that the desired correlation between the re-
sults obtained in the laboratory with nonhuman animals and the 
outcomes for human patients is lacking. One of the implica-
tions of such a poor correlation is that the results obtained with 
animals may be worse than futile for humans, they may actu-
ally be harmful since they furnish misplaced confidence about 
the safety and effectiveness of drugs, procedures etc. Instances 
where testing in animal models failed to predict disastrous re-
actions in humans include the widely referred to cases of tha-
lidomide and diethylstilbestrol, and more recently the trial of 
TGN1412.
We suggest that three main reasons explain the poor transla-
tion between animal experiments and their application to hu-
man patients. First, and perhaps most obviously, the basic het-
erogeneity of living organisms means that differences in physi-
ology, metabolism etc., contribute to different outcomes across 
species (LaFollette and Shanks 1996). Second, it has recently 
become apparent that animal experimentation is often poorly 
conducted and inappropriately evaluated (Pound et. al. 2004), 
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again limiting the possible contribution information derived 
from this practice can make to human health and wellbeing. 
Third, new research has shown that environmental factors can 
skew scientific results. For instance small cage size, lack of 
environmental stimulation, high levels of noise etc. contribute 
to animal stress which in turn has a demonstrated impact on 
physiology and the reliability of scientific data obtained from 
animals (Baldwin et al. 2006; Burwell and Baldwin 2006).
A number of strategies have been deployed by researchers 
to address these epistemological shortcomings. We will briefly 
outline these strategies before showing how animal patients 
can address such shortcomings in a more comprehensive man-
ner. We will later expand on the additional ethical advantage of 
our approach.
Some researchers have sought to address the inadequate ex-
perimental design common to animal-based medical research 
and toxicity testing. Closer scrutiny of these practices has re-
vealed that animal-based trials are rarely randomized (a process 
intended to avoid bias in selection of individuals to receive a 
drug or treatment being investigated that might skew trial re-
sults) or blinded during allocation and outcome assessment 
(blinding is a means of addressing bias in how outcomes are 
measured). These critics and would-be reformers argue that 
given this inherent bias it is unsurprising that the majority of 
“positive” animal trials are rarely reproduced during subse-
quent human testing (Hackam 2007). On this view, improved 
experimental methods would likely result in better translation 
from animal studies to human clinical benefit, though it is diffi-
cult to see how such an approach would meet concerns regard-
ing fundamental biological differences between humans and 
experimental animals. 
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Other biomedical practitioners take a different approach. 
Self-identified “translational researchers” promulgate an alter-
native “discovery-based” investigative strategy that is directed 
by clinical and epidemiological observations of human dis-
eases, rather than the bottom-up bench-to-bedside hypothesis-
testing practice that characterized much of the animal-based 
research in late-twentieth century biomedicine (Marincola 
2007). They argue that this comparative and clinically-focused 
research strategy (which attends to naturally occurring human 
and nonhuman animal diseases) has the potential to solve many 
of the present epistemological quandaries. However the advan-
tages of such an approach remain speculative and as yet un-
proven. Beyond the different philosophical justifications given 
for the utility and fallibility of extrapolation, there is a paucity 
of empirical work on the relative contribution of different types 
of scientific research to medical advances. The merits to sci-
entific progress of basic, observational, clinical, animal model 
based, epidemiological and in vitro studies etc. remains largely 
unknown. Commenting over twenty-years ago on a poorly un-
dertaken attempt to make such an assessment, Richard Smith 
stated: “we need to research research so that we can allot funds 
in a more intelligent and less empirical and… anecdotal way” 
(Smith 1987, 1406). Unfortunately this deficit is yet to be recti-
fied.
As will be explained below, the animal-as-patient offers 
a way of overcoming each of the translational shortcomings 
identified above, and in so doing enhances the quality of data 
captured in animal experiments, making such data more direct-
ly applicable to human patients. 
The heterogeneity challenge is addressed because, as will be 
recalled from our definition of animal patients, these creatures 
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must be natural or spontaneous models of disease. Though 
systematic research on this question is yet to be undertaken, 
our provisional hypothesis is that such spontaneous models 
are epistemologically superior to other model types and they 
hold this promise for at least two reasons. In the first instance 
it would seem that treatments tested on natural animal models 
are more likely to function in a way analogous to how they will 
perform in humans because, just like humans suffering from a 
particular disease, naturally occurring models have not had a 
disease or condition artificially imposed on them. Theoretically 
at least, imposing a disease on an animal to which that animal is 
not naturally predisposed, and then using the resulting creature 
as a research subject, appears problematic in a way that under-
taking research on a spontaneous model does not. Second, there 
are empirical cases that support this hypothesis. For instance, 
the hemophilia in dogs noted above and widely reported as an 
exemplar of predictive animal models in the pro-testing litera-
ture, is an example of the successful deployment of a number 
of different spontaneous models to characterize the variety of 
patho-physiological mechanisms that cause hemophilias in 
humans. In this case, geneticists, veterinarians, biomedical re-
searchers and hematologists worked together to identify, char-
acterize, and verify these breed-specific canine diatheses with 
a view to developing knowledge that benefited the health and 
well-being of individual humans. Rather than spend time and 
resources attempting to produce an artificial simulacrum of a 
human pathology, research was directed towards understand-
ing the etiology and patho-physiology of an analogous canine 
disease. These creatures could then function as a source of bio-
materials, as well as predictive models of human disease. 
The key to the success of this type of animal-centered clinical 
research has been a reinvestment in the science of comparative 
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pathology, rather than any attempt to build a diseased animal 
on the bench-top. The potential of pet models to generate bio-
medical knowledge has been further enhanced by the extension 
of increasingly elaborate forms of medical care to companion 
animals. For example the utility of modern genomic medicine 
rests on an assumption that an individual’s pathology should be 
understood and hence characterized as a manifestation of the 
interaction between the organism and its environment. The re-
cently completed description of the canine genome has provid-
ed a facility to include the comparative investigation of gene/
environment interactions in the etiology and treatment of many 
of the diseases we share with our animal companions (Ostrand-
er 2000). On this basis there are a number of pilot studies and 
clinical trials being undertaken treating pet canines using drugs 
that have the potential to benefit human patients with similar 
types of cancer and malignancies (London et al. 2009; Vail et 
al. 2009). 
Treating animals as patients rather than disposable resources 
or tools will also support higher standards of care in animal 
experimentation and reduce the kind of methodological short-
comings that have plagued the practice. Arguably researchers 
accountable to animal owners may perceive animals in experi-
mentation as less expendable and more valuable than creatures 
purchased or bred for experimental purposes. Such an attitude 
may ensure data is collected in such a way that protocols and 
entire experiments are not needlessly repeated. Tracking and 
longer-term follow up of animals would also be enabled by the 
enrollment of animal patients through veterinary clinics. 
Finally, the use of animal patients can address the prob-
lem of environmental stressors which distort the outcomes of 
laboratory experimentation. Animal patients will deliver better 
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quality data because, where possible, they are taken away from 
the traumatic laboratory environment, removing the possibility 
that trial results are skewed by adverse or abnormal laboratory 
conditions. This will also more closely mirror the experience of 
human patients, since animal patients are functioning in their 
everyday context, like similarly afflicted humans.
The ethical problem
The ethical issues that arise with animal experimentation 
are perhaps more widely appreciated than the epistemological 
ones. In short, and without entering into the contested terri-
tory of different theoretical approaches to animal ethics (rights 
based, utilitarian etc.), a concern about the ethics of animal ex-
perimentation arises because it is a practice which both causes 
harm to those animals involved (either directly as part of the 
experiment or as a result of the conditions in which they are 
kept), and generally furnishes no compensating benefit to in-
dividual experimental animals or their species of a kind which 
might be considered to ameliorate such harms. It should be 
noted that although on first blush it might seem that appeal to 
the language of costs and compensating benefits to describe the 
ethical problem is to beg the question in favor of a utilitarian/
consequentialist approach; this is not the case. Distributive jus-
tice frameworks can also appeal to a fair allocation of burdens 
and benefits in a way that is entirely consistent with a non-
consequentialist ethics. 
The current strategy adopted to address these ethical issues, 
and one widely favored amongst scientists and animal research 
ethics committees, is to suggest that a kind of truce or agree-
able middle ground is possible if Russell and Burch’s 3Rs are 
followed i.e. to Replace, Reduce and Refine the use of animals 
in experimentation (Smith 2001). The impetus provided by the 
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3Rs is for researchers to use alternative “non-sentient” models 
when they are available (Replace); to use as few animals as pos-
sible to generate the predictive data (Reduce); and to develop 
and deploy techniques to minimize animal pain and suffering 
(Refine). The 3Rs’ focus is explicitly on welfare, on improving 
the conditions borne by the nonhuman animal subjected to the 
experiment and so begins from the premise that provided at-
tempts are made to fulfill the 3Rs, then the practice of animal 
experimentation is itself morally permissible. According to the 
3Rs, animals who qualify as experimental subjects (i.e., those 
who are not excluded by virtue of the Replacement and Re-
duction strategies) are still treated as expendable tools and are 
generally killed at the experiment’s completion or after partici-
pating in a series of experiments. The 3Rs also do not attempt 
to address the deeper epistemological issues implicated in ex-
perimentation, rather they are predicated on the fact that ex-
perimentation is scientifically sound. So although the 3Rs can 
meet some of the ethical concerns with experimentation, they 
do little to satisfy those who doubt the epistemological validity 
of these animal-modeling practices. Implementation of the 3Rs 
may however unintentionally deliver epistemological benefits. 
For instance, the pursuit of replacement strategies might result 
in the collection of higher quality data. 
As noted above, treating animals as patients provides a 
means of dealing with these epistemological issues, while si-
multaneously addressing substantive ethical questions. Regard-
ing animals as patients leads to a significant shift in the balance 
of harms to benefits for animals involved in research. Unlike 
conventional experimentation on nonhuman animals, if an indi-
vidual animal is suffering from a particular disease or condition 
and is treated as a patient, then they may receive any benefits 
that flow from the experimental drug or treatment they receive, 
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just as human participants may in Phase II and III clinical trials 
(Phase II trials test for safety and efficacy and involve a small 
group of participants suffering from a particular disease or con-
dition that a drug or intervention seeks to treat, while Phase III 
trials enroll an expanded patient cohort). This is not to deny 
that animal patients may be harmed (just as human participants 
in clinical trials may), but simply to affirm that harm is not an 
inevitable outcome of patient based experimental practice. In 
addition to individual animals potentially benefiting through 
receiving an effective treatment, animals involved in research 
are not routinely killed, nor are otherwise healthy animals ex-
posed to alien diseases. Beyond any individual benefit, the data 
collected as part of the comparative research strategy can also 
feed into veterinary medicine in terms of both baseline biologi-
cal knowledge about a particular natural disease or condition, 
as well as mechanisms to treat such diseases and conditions. 
This is in stark contrast to animal experimentation as cur-
rently practiced which (unless specifically oriented to veteri-
nary questions) is solely concerned with deriving benefits and 
knowledge for human clinical medicine. 
As discussed above, on a patient based approach it is pos-
sible to conceive of moving much experimentation out of the 
laboratory, a source of both ethical and epistemological con-
cern. The frequently sterile conditions in which experimental 
animals are kept with the lack of nurturing, an absence of ac-
cess to their fellow animals and species normal activities etc., 
present major ethical hurdles which presumably do not exist 
if patients are living in their usual ‘home’ environment, being 
cared for by their owners. 
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4. The limitations of animal patients 
Though we argue that animal patients demonstrate both 
epistemological and ethical promise, the limitations inherent in 
such an approach need to be acknowledged. 
There will not be spontaneous models available for all the 
diseases suffered by humans. This seems to be clearly the case 
where diseases and pathologies are the result of the particular 
range of options and choices available to humans which are 
not readily available to other creatures - for instance humans 
can smoke, consume recreational drugs, eat large quantities of 
fast food etc. and all these behaviors result in well recognized 
adverse health outcomes, conditions and diseases. The relation-
ships we now develop with our companion animals, however, 
mean they may increasingly experience similar diseases to us. 
For instance the recent rise in lifestyle diabetes among cats ap-
pears to furnish a spontaneous model for human lifestyle in-
duced diabetes. A further limitation of this approach is that the 
use of animals in testing for disease only represents one way 
in which animals are used in research. Nonhuman animals are 
also used in toxicology testing, vaccine development, for edu-
cation and research training etc. Where the purpose of the ex-
periment does not relate to examining diseases or conditions, 
animal patients are not immediately applicable. 
5. Conclusion
Adopting a patient based approach to experimentation on 
nonhuman animals would represent a significant departure 
from the status quo. It would result in a much more limited and 
modest experimentation, as fewer animals (both in raw num-
bers and in terms of animal species) would qualify as patient 
models compared to those currently deployed, and the range 
of diseases and conditions investigated would be curtailed. 
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However, given the epistemological and ethical problems that 
continue to plague the practice of animal experimentation, it 
is a strategy that is surely worth evaluation. We maintain that 
construing animals as patients rather than disposable tools or 
materials can facilitate a shift in how they are both regarded 
and in turn treated in experimentation. Such a re-conceptualiz-
ing move can highlight similarities in experimentation as prac-
ticed on human and nonhuman animals that might otherwise 
be passed over, and can therefore enable lessons learned from 
experiences with the former to be extended to the latter. The 
patient based approach is also attractive because it represents a 
type of compromise, conceding something to the two opposed 
sides of the debate over animal testing, while failing to assent 
to either extreme. The patient model effectively represents a 
denial both that all experimentation undertaken is essential to 
safe and theoretically well-grounded medicine, or that all ex-
perimentation is futile and should be abolished. It should also 
be clear that this proposal does not represent idle philosophi-
cal speculation entirely untethered to reality; experience with 
pet models shows the empirical plausibility of animal patients 
when considered in terms of data obtained and the willingness 
of owners to participate in such research. Even if the patient 
model in its strictly articulated form proves too radical to be 
widely adopted, it offers a new position in an old debate and a 
way of re-conceptualizing the territory that has the potential to 
move forward reform of animal experimentation.
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